Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Technology evaluation: SAGE, Genzyme molecular oncology.

Bartlett J.

Curr Opin Mol Ther. 2001 Feb;3(1):85-96. Review.

PMID:
11249736
2.

Genzyme backs Osiris, despite Prochymal flop.

Allison M.

Nat Biotechnol. 2009 Nov;27(11):966-7. doi: 10.1038/nbt1109-966. No abstract available.

PMID:
19898434
3.

Comparison of the Inverness Medical Acceava Strep A test with the Genzyme OSOM and Quidel QuickVue Strep A tests.

Rogo T, Schwartz RH, Ascher DP.

Clin Pediatr (Phila). 2011 Apr;50(4):294-6. doi: 10.1177/0009922810385675. Epub 2010 Nov 22.

PMID:
21098521
4.

Genzyme: 15 years of cell and gene therapy research.

De Bie C.

Regen Med. 2007 Jan;2(1):95-7.

5.

Comparison of the Inverness Medical Acceava Strep A test with the Genzyme OSOM and Quidel QuickVue Strep A tests.

Rogo T, Schwartz RH, Ascher DP.

Clin Pediatr (Phila). 2010 Nov;49(11):1050-2. doi: 10.1177/0009922810376235. Epub 2010 Aug 19.

PMID:
20724334
6.

Transgenic antithrombin III (Genzyme).

Yeung PK.

IDrugs. 2000 Jun;3(6):669-73.

PMID:
16096931
7.

Ecallantide (Dyax/Genzyme).

Lehmann A.

Curr Opin Investig Drugs. 2006 Mar;7(3):282-90.

PMID:
16555689
8.

Technology evaluation: cystic fibrosis therapy, Genzyme.

Cockett MI.

Curr Opin Mol Ther. 1999 Apr;1(2):279-83. Review.

PMID:
11715952
9.

alpha-glucosidase (CHO) (Genzyme).

Lachmann RH.

Curr Opin Investig Drugs. 2004 Oct;5(10):1101-10. Review.

PMID:
15535432
10.

Why Genzyme can charge so much for Cerezyme.

Anand G.

Wall St J (East Ed). 2005 Nov 16:A15. No abstract available.

PMID:
16502533
11.

Continous bioprocessing: an interview with Konstantin Konstantinov from Genzyme. Interviewed by Prof. Alois Jungbauer and Dr. Judy Peng.

Konstantinov K.

Biotechnol J. 2011 Dec;6(12):1431-3. doi: 10.1002/biot.201100464. No abstract available.

PMID:
22162493
12.

Alpha-galactosidase - Genzyme General. Fabrazyme, agalsidase beta, recombinant human alpha-galactosidase A.

[No authors listed]

Drugs R D. 2003;4(2):115-8. No abstract available.

PMID:
12718567
13.
14.

Osiris seals billion-dollar deal with Genzyme for cell therapy.

Mack GS.

Nat Biotechnol. 2009 Feb;27(2):106-7. doi: 10.1038/nbt0209-106. No abstract available.

PMID:
19204671
15.

Analytical performance of the Genzyme LipoPro Lp(a) kit for plasma lipoprotein(a)-cholesterol assay.

Gaw A, Brown EA, Gourlay CW, Bell MA.

Br J Biomed Sci. 2000;57(1):13-8.

PMID:
10892028
16.

Tasidotin HCl (Genzyme).

Rasila KK, Verschraegen C.

Curr Opin Investig Drugs. 2005 Jun;6(6):631-8. Review. No abstract available.

PMID:
15988915
17.

As Genzyme flounders, competitors and activist investors swoop in.

Allison M.

Nat Biotechnol. 2010 Jan;28(1):3-4. doi: 10.1038/nbt0110-3. No abstract available.

PMID:
20062016
18.

[Application of the insulating material teflon--pladgets (Genzyme-USA) during the microvascular decompression].

Andrychowski J, Czernicki Z.

Neurol Neurochir Pol. 2001;35 Suppl 5:26-9. Polish.

PMID:
11935676
19.

Genzyme resumes shipping as Sanofi-aventis hovers.

Ratner M.

Nat Biotechnol. 2010 Oct;28(10):994. doi: 10.1038/nbt1010-994c. No abstract available.

PMID:
20944572
20.

Genzyme, though unique, could be a bellwether for US biotech.

Dolgin E.

Nat Med. 2011 Feb;17(2):145. doi: 10.1038/nm0211-145. No abstract available. Erratum in: Nat Med. 2011 Mar;17(3):237.

PMID:
21297597

Supplemental Content

Support Center